Pleural
Reactive Oxygen Species Drive Cell Migration and PD-L1 Expression via YB-1 Phosphorylation in Pleural Mesothelioma
Antioxidants 2026 January 17 [Link] Muhammad Hashim, Gerald Timelthaler, Dominik Kirchhofer, Beatrice Irina Kudlacek, Berta Mosleh, Katharina Sinn, Ezzat Mohamed Awad, Mir Alireza Hoda, Bettina Grasl-Kraupp, Balazs Dome, Walter Berger, Georg Krupitza, Karin Schelch, Michael Grusch Abstract Reactive oxygen species (ROS)-induced aberrant oncogenic signalling has been proposed to mediate the progression and development of pleural…
Read MorePD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma
Cells 2026 January 19 [Link] Milija Gajić, Vesna Ćeriman Krstić, Natalija Samardžić, Ivan Soldatović, Sofija Glumac, Milena Jovanović 4, Milan Savić, Mihailo Stjepanović, Spasoje Popević, Ruža Stević, Nikola Čolić, Katarina Lukić, Vladimir Milenković, Ivan Milivojević, Ivana Sekulović Radovanović, Dragana Jovanović Abstract Malignant pleural mesothelioma (MPM) is a very aggressive tumor. The prognostic value of PD-L1…
Read MorePrognostic value and clinical significance of tumoral PD-L1 and stromal α-SMA expression in diffuse pleural mesothelioma
Neoplasma 2026 February [Link] Yeqi Sun, Lan Li, Lei Cai, Jihua Yang, Jun Qian, Fajiu Wang, Lifeng Wang Abstract Diffuse pleural mesothelioma (PM) is a rare malignant neoplasm with an extremely poor prognosis. Prognostic assessment remains challenging, highlighting the urgent need for reliable biomarkers to guide precise and effective therapy. Programmed death ligand 1 (PD-L1)…
Read MoreCancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma
Cancer Science 2026 January 20 [Link] Aito Yoshida, Shinji Abe, Toshihiro Izumi, Satoshi Itakura, Keichiro Yamada, Takuya Wada, Takaaki Yamamoto, Chiemi Sato, Atsushi Mitsuhashi, Hirokazu Ogino, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi, Mika K Kaneko, Yukinari Kato, Yasuhiko Nishioka Abstract Pleural mesothelioma (PM) is a malignancy with a poor prognosis owing to its resistance to…
Read MoreRisk Factors of Hematological Toxicity of Mesothelioma Treatment-A Territory-Wide Retrospective Study
Thoracic Cancer 2026 January [Link] Wang Chun Kwok, Desmond Yat Hin Yap, Isaac Sze Him Leung, James Chung Man Ho Abstract Background: While chemotherapy remains the treatment of choice for mesothelioma, it carries significant toxicities, especially hematological toxicity. Methods: We conducted this territory-wide retrospective study in Hong Kong to investigate the prevalence and risk factors…
Read MoreMesothelioma Contrast Pharmacokinetics: A Feasibility Trial of the Use of Pharmacokinetic Analysis in Small-Volume Pleural Malignancy
Radiology. Cardiothoracic Imaging 2026 February [Link] Gordon W Cowell, Selina Tsim, David B Stobo, Colin Noble, Catherine A Humphreys, Rosie Woodward, John E Foster, Craig Dick, Kevin G Blyth Abstract Purpose To assess the feasibility of dynamic contrast-enhanced (DCE) MRI-derived pharmacokinetic factor acquisition and performance in patients with suspected small-volume pleural malignancy. Materials and Methods…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreNintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)
Lung Cancer 2026 March [Link] Omar Abdel-Rahman, Paul Taylor, Mary O’Brien, Jo Raskin, Claudio Dazzi, Veerle Surmont, Sabrina Zonato, Robin Young, Anne-Claire Toffart, Petra Jankowska, Adam Hassani, Sandrine Marreaud, Luc Boone, Sanjay Popat Abstract Introduction: Pleural mesothelioma (PM) is a lethal malignancy in which angiogenesis and progressive fibrosis drives disease. We evaluated angiogenesis inhibition using…
Read MoreArtificial Intelligence in Pleural Diseases: Current Applications and Next Steps
Thoracic Research and Practice 2026 January 30 [Link] Ferhan Karataş, Öner Dikensoy Abstract Pleural diseases pose a significant burden on healthcare systems due to diagnostic challenges and high costs. Artificial intelligence (AI) has the potential to provide faster, more accurate, and more reliable results in the diagnosis of these diseases. This review evaluates the current…
Read MoreReal-world outcomes of first-line immunotherapy and subsequent systemic therapies in pleural mesothelioma: a multicenter study in China
Translational Lung Cancer Research 2025 December 31 [Link] Binhe Tian, Boyu Sun, Zixiang Zhou, Shuman Kuang, Jiongyuan Li, Weixuan Pan, Zhe Zhu, Xiaoyan Si, Li Zhang, Jun Liu, Juhong Shi, Fang Wu, Haitao Zhao, Hanping Wang Abstract Background: Pleural mesothelioma (PM) has a poor prognosis, and immune checkpoint inhibitors (ICIs) have reshaped first-line therapy. However,…
Read More
Skip to content